Oncology Research Unit, Division of Urology, University of Zurich and University Hospital, Zurich, Switzerland.
J Virol. 2012 Aug;86(16):8461-71. doi: 10.1128/JVI.00005-12. Epub 2012 May 30.
The role of the polyomavirus BK (BKV) large tumor antigen (L-Tag) as a target of immune response in patients with prostate cancer (PCa) has not been investigated thus far. In this study, we comparatively analyzed humoral and cellular L-Tag-specific responsiveness in age-matched patients bearing PCa or benign prostatic hyperplasia, expressing or not expressing BKV L-Tag-specific sequences in their tissue specimens, and in non-age-matched healthy individuals. Furthermore, results from patients with PCa were correlated to 5-year follow-up clinical data focusing on evidence of biochemical recurrence (BR) after surgery (prostate specific antigen level of ≥0.2 ng/ml). In peripheral blood mononuclear cells (PBMC) from patients with PCa with evidence of BR and BKV L-Tag-positive tumors, stimulation with peptides derived from the BKV L-Tag but not those derived from Epstein-Barr virus, influenza virus, or cytomegalovirus induced a peculiar cytokine gene expression profile, characterized by high expression of interleukin-10 (IL-10) and transforming growth factor β1 and low expression of gamma interferon genes. This pattern was confirmed by protein secretion data and correlated with high levels of anti-BKV L-Tag IgG. Furthermore, in PBMC from these PCa-bearing patients, L-Tag-derived peptides significantly expanded an IL-10-secreting CD4(+) CD25(+(high)) CD127(-) FoxP3(+) T cell population with an effector memory phenotype (CD103(+)) capable of inhibiting proliferation of autologous anti-CD3/CD28-triggered CD4(+) CD25(-) T cells. Collectively, our findings indicate that potentially tolerogenic features of L-Tag-specific immune response are significantly associated with tumor progression in patients with BKV(+) PCa.
迄今为止,多瘤病毒 BK(BKV)大肿瘤抗原(L-Tag)作为前列腺癌(PCa)患者免疫反应的靶标尚未被研究。在这项研究中,我们比较分析了年龄匹配的患有 PCa 或良性前列腺增生的患者、组织标本中表达或不表达 BKV L-Tag 特异性序列的患者以及非年龄匹配的健康个体的体液和细胞 L-Tag 特异性反应性。此外,还将 PCa 患者的结果与 5 年随访的临床数据相关联,重点关注手术后生化复发(BR)的证据(前列腺特异性抗原水平≥0.2ng/ml)。在具有 BR 和 BKV L-Tag 阳性肿瘤证据的 PCa 患者的外周血单核细胞(PBMC)中,用源自 BKV L-Tag 的肽刺激,但不是源自 Epstein-Barr 病毒、流感病毒或巨细胞病毒的肽刺激,诱导出一种特殊的细胞因子基因表达谱,其特征是白细胞介素-10(IL-10)和转化生长因子β1 的高表达和γ干扰素基因的低表达。该模式通过蛋白分泌数据得到证实,并与高水平的抗 BKV L-Tag IgG 相关。此外,在这些患有 PCa 的患者的 PBMC 中,L-Tag 衍生肽显著扩增了具有效应记忆表型(CD103(+))的分泌 IL-10 的 CD4(+) CD25(+(高))CD127(-) FoxP3(+) T 细胞群,能够抑制自体抗 CD3/CD28 触发的 CD4(+) CD25(-) T 细胞的增殖。总之,我们的发现表明,BKV(+)PCa 患者中 L-Tag 特异性免疫反应的潜在耐受特征与肿瘤进展显著相关。